Histologically confirmed or suspected HPV associated squamous cell carcinoma of the oropharynx.
p16 immunohistochemistry is the surrogate marker for HPV positivity and will be scored as positive if there is strong and diffuse nuclear and cytoplasmic staining present in greater than 70% of the tumor specimen. (A negative result excludes the patient from the trial)
In the case of equivocal p16, High Risk HPV (HR HPV), In-Situ Hybridization (ISH) / Polymerase Chain Reaction (PCR) may be performed to determine HPV positivity
Staging will be based on cross sectional imaging investigations and clinical exam.
Patients who initially have an unknown primary but subsequently have a primary site identified on pathology after surgical resection may be included in the study.
Multidisciplinary team decision to treat with primary transoral resection and neck dissection.
Patients considered fit for surgery and adjuvant therapy.
Aged 18 or over.
Written informed consent provided.
You may not be if
HPV negative squamous cell carcinomas of the head and neck
T4 and/or T1-T3 tumors where transoral surgery is considered not feasible or there is a high likelihood of positive margins.
AJCC TNM 7th edition N2c-N3 nodal disease (or AJCC TNM 8th edition N2-N3 nodal disease) or high likelihood of gross extranodal extension.
Patients for whom transoral surgery and neck dissection is not considered the primary treatment modality.
Distant metastatic disease as determined by routine pre-operative staging radiological investigations e.g. CT thorax and upper abdomen or PET CT.
Women who are pregnant or breastfeeding
Prior history of radiation to head and neck
Clareo Health | Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma
